evan yu, md, regarding combination pembrolizumab and olaparib in mcrpc
Published 5 years ago • 62 plays • Length 2:18
Download video MP4
Download video MP3
Similar videos
-
1:14
dr. yu on combining pembrolizumab and olaparib in mcrpc
-
2:58
evan yu, md, elaborates on the results from keynote 365 in mcrpc
-
2:38
keynote-365 cohort a: pembrolizumab plus olaparib in docetaxel-pretreated patients with mcrpc
-
1:23
nicholas vogelzang, md, fasco, facp, regarding combination pembrolizumab and olaparib in mcrpc
-
1:29
evan yu, md, on combining checkpoint inhibitors in metastatic castration-resistant prostate cancer
-
22:00
how i live with stage 4 metastatic prostate cancer | mark's story | the patient story
-
15:27
how does prostate cancer chemotherapy work? | prolonged survival & improved cure rates | pcri
-
18:21
decisional tools to determine need for biopsy and re-biopsy in men with elevated psas
-
1:40
evan yu, md, considers when sipuleucel-t should be used in treatment of mcrpc
-
50:29
treatments for advanced prostate cancer in 2022 | evan yu, md | pcri
-
9:45
what is the role chemotherapy in modern day prostate cancer treatment? | evan yu, md explains | pcri
-
11:50
prostate cancer: optimizing the use of newer agents - dr. evan yu, part 1
-
46:19
binaytara foundation_ dr. evan yu's talk on metastatic prostate cancer
-
0:44
propel: gene-by-gene efficacy of olaparib and abiraterone in mcrpc
-
1:10
dr. yu on the future of castration-sensitive prostate cancer
-
6:34
asco22 prostate cancer updates | evan yu, md | seattle cancer care alliance
-
0:41
treating advanced hormone-sensitive prostate cancer
-
11:50
prostate cancer: optimizing the use of newer agents - dr. evan yu, part 3
-
3:38
prostate cancer: optimizing the use of newer agents - dr. evan yu, part 4
-
11:50
prostate cancer: optimizing the use of newer agents - dr. evan yu, part 2
-
1:04
qme selection process - dr eric prestin and prostitute...do you want to lose your settlement?
Clip.africa.com - Privacy-policy